[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001268426A1 - Stable gabapentin containing more than 2o ppm of chlorine ion - Google Patents

Stable gabapentin containing more than 2o ppm of chlorine ion

Info

Publication number
AU2001268426A1
AU2001268426A1 AU2001268426A AU6842601A AU2001268426A1 AU 2001268426 A1 AU2001268426 A1 AU 2001268426A1 AU 2001268426 A AU2001268426 A AU 2001268426A AU 6842601 A AU6842601 A AU 6842601A AU 2001268426 A1 AU2001268426 A1 AU 2001268426A1
Authority
AU
Australia
Prior art keywords
ppm
chlorine ion
stable gabapentin
stable
gabapentin containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268426A
Inventor
Michael Pesachovich
Gideon Pilarski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22788993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001268426(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001268426A1 publication Critical patent/AU2001268426A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Pharmaceutical compositions containing substantially pure and stable gabapentin are disclosed wherein gabapentin contains an anion of a mineral acid, such as chloride, in amounts greater than 20 ppm.
AU2001268426A 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion Abandoned AU2001268426A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21196700P 2000-06-16 2000-06-16
US60211967 2000-06-16
PCT/US2001/019100 WO2001097612A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Publications (1)

Publication Number Publication Date
AU2001268426A1 true AU2001268426A1 (en) 2002-01-02

Family

ID=22788993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268426A Abandoned AU2001268426A1 (en) 2000-06-16 2001-06-15 Stable gabapentin containing more than 2o ppm of chlorine ion

Country Status (12)

Country Link
US (1) US6531509B2 (en)
EP (1) EP1289364B1 (en)
AT (1) ATE255891T1 (en)
AU (1) AU2001268426A1 (en)
CA (1) CA2410867C (en)
DE (2) DE60101476T2 (en)
DK (1) DK1289364T3 (en)
ES (1) ES2193008T3 (en)
IL (1) IL153398A0 (en)
PT (1) PT1289364E (en)
TR (1) TR200302296T4 (en)
WO (1) WO2001097612A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ200339A3 (en) * 2000-06-16 2003-06-18 Teva Pharmaceutical Industries Ltd. Stable gabapentin exhibiting neutral pH value
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
DE60315258T2 (en) * 2002-12-20 2008-05-08 Dynogen Pharmaceuticals Inc., Waltham TREATMENT OF NON-PAINTING BLADDER TROUBLESHOOTING WITH MODULATORS OF THE ALPHA 2 DELTA SUB-UNIT OF THE CALCIUM CHANNEL
US20040198822A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmacueticals, Inc. Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
WO2005046566A2 (en) * 2003-08-04 2005-05-26 Sun Pharmaceutical Industries Limited Stable gabapentin containing composition
WO2005041928A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for ehnanced absorption of iron
US20050187295A1 (en) * 2004-02-19 2005-08-25 Surendra Kalyan Processes for the preparation of gabapentin
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN101462975B (en) * 2008-08-19 2012-07-25 宁波九胜创新医药科技有限公司 Preparation of high-purity gabapentin
CN116693410B (en) * 2023-06-08 2024-06-07 浙江竹子制药有限公司 Preparation method of gabapentin with controllable particle size

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (en) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-aminomethyl-1-cycloalkaneacetic acids and their esters, processes for their preparation and medicaments containing these compounds
DE2611690A1 (en) 1976-03-19 1977-09-22 Goedecke Ag CYCLIC SULFONYLOXYIMIDE
US4894476A (en) 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
DE3928182A1 (en) 1989-08-25 1991-02-28 Goedecke Ag METHOD FOR PRODUCING GABAPENTIN
DE3928183A1 (en) 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
DE3928184A1 (en) 1989-08-25 1991-02-28 Goedecke Ag METHOD FOR PRODUCING CYCLIC AMINO ACID DERIVATIVES AND INTERMEDIATE PRODUCTS
US5132451A (en) 1989-08-25 1992-07-21 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
AU633612B2 (en) 1989-08-25 1993-02-04 Warner-Lambert Company Improved process for cyclic amino acid anticonvulsant compounds
US5319135A (en) 1989-08-25 1994-06-07 Warner-Lambert Company Process for cyclic amino acid anticonvulsant compounds
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
IL119890A (en) * 1996-12-24 2002-03-10 Teva Pharma Gabapentin form iii and preparation of gabapentin form ii
WO1999059573A1 (en) * 1998-05-15 1999-11-25 Warner-Lambert Company Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
PL205145B1 (en) * 1998-05-15 2010-03-31 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
FR2781793B1 (en) 1998-08-03 2001-07-20 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
US6294198B1 (en) 1999-08-24 2001-09-25 Purepac Pharmaceutical Co. Pharmaceutical tablet formulation containing gabapentin with improved physical and chemical characteristics and method of making the same
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same

Also Published As

Publication number Publication date
IL153398A0 (en) 2003-07-06
EP1289364B1 (en) 2003-12-10
DE60101476T2 (en) 2004-05-27
ES2193008T3 (en) 2004-07-01
DK1289364T3 (en) 2004-04-13
EP1289364A1 (en) 2003-03-12
US6531509B2 (en) 2003-03-11
US20020061931A1 (en) 2002-05-23
CA2410867A1 (en) 2001-12-27
CA2410867C (en) 2003-12-09
DE60101476D1 (en) 2004-01-22
ATE255891T1 (en) 2003-12-15
TR200302296T4 (en) 2004-02-23
EP1289364A4 (en) 2003-08-06
DE1289364T1 (en) 2003-09-18
ES2193008T1 (en) 2003-11-01
PT1289364E (en) 2004-04-30
WO2001097612A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU2001268426A1 (en) Stable gabapentin containing more than 2o ppm of chlorine ion
YU31399A (en) Nitric oxide synthase inhibitors
HK1045705A1 (en) Silicone gel containing salicylic acid
WO1998023249A3 (en) Oral compositions containing fluoride, pyrophosphate, peroxide, and nonionic and/or amphoteric surfactants
AU5677099A (en) New solid dose form of nanoparticulate naproxen
MXPA04004109A (en) Anhydrous cosmetic compositions containing quaternary ammonium compounds.
AU3722295A (en) Dentifrice compositions
TW200510375A (en) New compounds
GR3034792T3 (en) Dentifrice compositions
IL151313A0 (en) Lipase containing pharmaceutical compositions
ATE198143T1 (en) TOOTHPASTES
DE69905170D1 (en) Thiazolopyrimidinderivate
EP1499590B8 (en) Piperidine derivatives as potassium channel blockers
MXPA02006826A (en) Cell division inhibitors and process for producing the same.
MXPA04006542A (en) Stable oral compositions comprising casein phosphopeptide complexes and flouride.
MXPA05012901A (en) Clear, stable topical compositions of clarithromycin and processes for their preparation.
IL150257A0 (en) Galactomaninan oligosaccharides, pharmaceutical compositions containing the same and methods for the production thereof
RS90904A (en) Novel perindopril salt and pharmaceutical compositions containing same
CA2318398A1 (en) Novel peptides having biological activity
NO20014101L (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
SI1121127T1 (en) Oral pharmaceutical compositions containing buprenorphin
AU2249297A (en) Low ph germicidal iodine compositions having enhanced stability
YU95302A (en) Stable gabapentin having ph within a controlled range
AU2002303856A1 (en) Gpe analogs and peptidomimetics